Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785871 · ClinicalTrials.gov registry record
Hypertension, Brain Clearance, and Markers of Neurodegeneration
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 80
- Enrollment target
NCT05785871 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 80 participants.
The verdict
NCT05785871 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The purpose of this research study is to measure cerebrospinal fluid (CSF) clearance in subjects with and without high blood pressure. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance. Impaired removal of proteins from the aging brain causes their buildup and may contribute to an increased risk for Alzheimer's disease. It is also suspected that clearance may be related to the health of vessels carrying the blood throughout the brain. It is known that high blood pressure damages blood vessels and thus may impair clearance. In this project we will examine if having high blood pressure is related to impaired brain clearance and whether treating high blood pressure improves clearance and reduces buildup of Alzheimer's disease-related proteins. Participants will be asked to undergo a medical examination, testing of memory, brain imaging (both magnetic resonance and positron emission tomography, and spinal tap at the beginning of the study and 1 -2 years later.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05785871
The ClinicalTrials.gov registry entry for NCT05785871 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05785871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05785871 about?
NCT05785871 is a clinical study titled "Hypertension, Brain Clearance, and Markers of Neurodegeneration". The purpose of this research study is to measure cerebrospinal fluid (CSF) clearance in subjects with and without high blood pressure. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance. Impaired removal of proteins fro...
What is the current status of trial NCT05785871?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2020-11-18. Estimated completion is 2025-06-30.
Who is sponsoring clinical trial NCT05785871?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.